论文部分内容阅读
化疗是中晚期肺癌主要治疗手段之一,目前对于非小细胞肺癌(NSCLC)化疗疗效不够理想。长春瑞滨(Navelbine.NVB)作为一种新型半合成长春碱类抗癌药,为我们提供了一条新的治疗途径。我科1996年10月～1999年10月,采用长春湍滨联合顺铂(cisplatin,DDP)治疗Ⅲ_b—Ⅳ期NSCLC16例。并与MVP方案作对照,现将结果分析如下:1 临床资料1.1 病例资料:1996年10月～1999年10月,我科共收治NSCLS患者36例,均经细胞学或病理学确诊。治疗组16
Chemotherapy is one of the main treatments for advanced lung cancer. Currently, the curative effect of chemotherapy for non-small cell lung cancer (NSCLC) is not ideal. As a new type of semi-synthetic vinblastine anticancer drug, Navelbine.NVB provides us with a new treatment. In our department from October 1996 to October 1999, 16 cases of stage III-b-IV NSCLC were treated with Changchun Sibin and cisplatin (DDP). And compared with the MVP program, the results are analyzed as follows: 1 Clinical data 1.1 Case data: From October 1996 to October 1999, our department received a total of 36 patients with NSCLS, were confirmed by cytology or pathology. Treatment group 16